carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'lcsm,(-blcsm)', 'atezo', 'sclc']
#asco22 skyscraper-02: ph iii, study of atezo+ce plus tira (a) or pbo (b) in pts with untreated es-sclc: os= 13.6 m(a)vs 13.6 m(b) pfs= 5.4m (a)vs 5.6 m (b) orr= 70.8% (a)vs 65.6 % (b) tox= more rash and pruritus
#lcsm 
#MedicalOncologist MSc Transl Res Univ Paris Sud   #LungCancer biology, immunotherapy, clinical trials #LCSM @myESMO faculty #OncoAlert   live to give